Eli Lilly and
$1,142.85Change from previous close: −0.61%Absolute change: −$7.00
At a glance
- Revenue growth
- +44.70%
- 2025 vs 2024
- Net income growth
- +94.90%
- 2025 vs 2024
- Net margin
- 31.7%
- 2024: 23.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 16,813 | 8,818 | 4,240 | 7,586 | 7,366 | 6,500 | 4,837 | 5,525 | 5,616 | 4,851 |
| Depreciation and amortization | 1,997 | 1,767 | 1,527 | 1,523 | 1,548 | 1,324 | 1,233 | 1,609 | 1,567 | 1,400 |
| Capital expenditure | -7,841 | -5,058 | -3,448 | -1,854 | -1,310 | -1,388 | -1,034 | -1,211 | -1,077 | -1,037 |
| Investing cash flow | -10,972 | -9,302 | -7,153 | -3,763 | -2,868 | -2,259 | -8,083 | 1,906 | -3,784 | -3,139 |
| Financing cash flow | -2,213 | 1,230 | 3,496 | -5,407 | -4,131 | -3,137 | -2,325 | -5,905 | 143 | -560 |
| Dividends paid | -5,384 | -4,680 | -4,069 | -3,536 | -3,087 | -2,687 | -2,410 | -2,312 | -2,192 | -2,159 |
| Share repurchases | -4,108 | -2,500 | -750 | -1,500 | -1,250 | -500 | -4,400 | -4,151 | -300 | -600 |
| Debt issued | 13,167 | 11,417 | 8,650 | 1,498 | 2,411 | 2,062 | 7,552 | 2,478 | 3,630 | 2,500 |
| Debt repaid | -5,116 | -2,516 | 0.0 | -1,560 | -1,909 | -1,771 | -2,866 | -3,207 | -631 | -0.2 |
| Effect of exchange rates | 372 | -297 | 169 | -168 | -206 | 216 | -89.9 | -63.6 | -20.5 | -236 |
| Net change in cash | 4,000 | 449 | 752 | -1,752 | 161 | 1,320 | -5,661 | 1,462 | 1,954 | 916 |
| Free cash flow | 8,972 | 3,760 | 792 | 5,731 | 6,056 | — | — | — | — | — |
| Levered free cash flow | 1,951 | 1,355 | 292 | 5,276 | 5,461 | 3,501 | 4,991 | 539 | 2,119 | 2,851 |